Improved pharmacokinetics of tryptamine prodrugs
An injectable composition of formula (I) or its salt addresses the need for rapid and sustained treatment of mental disorders by providing a safe and effective therapeutic solution.
Patent Information
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- REUNION NEUROSCIENCE INC
- Filing Date
- 2026-05-05
- Publication Date
- 2026-07-10
AI Technical Summary
Current treatments for mental disorders lack effective and safe injectable compositions that can provide rapid and sustained therapeutic effects.
An injectable composition comprising a compound of formula (I) or its pharmaceutically acceptable salt, administered in a dose of about 30 mg to about 50 mg based on free base, is developed for treating mental disorders.
The composition provides rapid and sustained therapeutic effects for mental disorders, offering a safe and effective treatment option.
Smart Images
Figure 00000000_0000_ABST
Abstract
Description
Abstract This invention describes an injectable composition comprising a compound of formula (I): (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, wherein the compound of formula (I) is present in a dose of about 30 mg to about 50 mg based on free base. A method for treating mental disorders is also described, comprising the step of administering a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof to a patient in need of treatment.
Claims
What is claimed is:
1. An injectable composition comprising a compound of Formula (I): or a pharmaceuticallyof Formula (I) is present at a dose of from about 30 mg to about 50 mg calculated as the free base, together with a pharmaceutically acceptable carrier.
2. An injectable composition comprising a compound of Formula (I): or a pharmaceuticallyof Formula (I) is present at a dose of 30 mg or 40 mg calculated as the free base, together with a pharmaceutically acceptable carrier.
3. The injectable composition defined in Claim 1 or Claim 2, wherein the compound of Formula (I) is the hydrochloride salt thereof.
4. The injectable composition defined in Claim 2, wherein the compound of Formula (I) is the hydrochloride salt thereof present at a dose of 33 mg or 44 mg.
5. The injectible composition defined in any one of Claims 1-4, wherein wherein the injectable composition is a subcutaneous injectable composition.
6. A method of treating a mental disorder comprising the step of administering to a patient in need of treatment a pharmaceutical composition comprising a compound of Formula (I): at a dose of from aboutfree base, together with a pharmaceutically acceptable carrier.
7. A method of treating a mental disorder comprising the step of administering to a patient in need of treatment a pharmaceutical composition comprising a compound of Formula (I):I) at a dose of about 30 mg or about 40 mg calculated as the free base, together with a pharmaceutically acceptable carrier.
8. The method defined in Claim 6 or Claim 7, wherein the compound of Formula (I) is the hydrochloride salt thereof.
9. The method defined in Claim 7, wherein the compound of Formula (I) is the hydrochloride salt thereof present at a dose of 33 mg or 44 mg.
10. A method of treating a mental disorder comprising the step of administering to a patient in need of treatment a pharmaceutical composition comprising a compound of Formula (I): at a dose of 1 mg / kgpharmaceutically acceptable carrier.
11. The method defined in any one of Claims 6-10, wherein the compound of Formula (I) has a duration of action of from about 2.5 hours to about 4.5 hours after administration.
12. The method defined in any one of Claims 6-10, wherein the compound of Formula (I) has a duration of action of about 3.5 hours or 3.7 hours after administration.
13. The method defined in any one of Claims 6-12, wherein the compound of Formula (I) has a Cmaxin the patient in the range of from about 1000 ng / mL to about 2000 ng / mL.
14. The method defined in any one of Claims 6-12, wherein the compound of Formula (I) has a Cmax in the patient in the range of from about 1500 ng / mL to about 1800 ng / mL.
15. The method defined in any one of Claims 6-14, wherein the compound of Formula (I) has a Tmaxin the patient in the range of from about 20 minutes 30 minutes.
16. The method defined in any one of Claims 6-14, wherein the compound of Formula (I) has a Tmaxin the patient in the range of about 15 minutes.
17. The method defined in any one of Claims 6-16, wherein the compound of Formula (I) is converted to a compound of Formula (II) after administration and the compound of Formulathe range of from about 100 ng / mL to about 300 ng / mL.
18. The method defined in any one of Claims 6-16, wherein the compound of Formula (I) is converted to a compound of Formula (II) after administrationI) and the compound of Formula (II) has a Cmax in the patient in the range of from about 120 ng / mL to about 300 ng / mL.
19. The method defined in any one of Claims 6-18, wherein the compound of Formula (I) is converted to a compound of Formula (II) after administration and the compound of Formulathe range of from about 60 minutes to about 150 min.
20. The method defined in any one of Claims 6-18, wherein the compound of Formula (I) is converted to a compound of Formula (II) after administration and the compound of Formulathe range of from about 60 minutes to about 80 min.
21. The method defined in any one of Claims 6-20, which demonstrates an average MEQ30 score in the patient of at least 50%.
22. The method defined in any one of Claims 6-20, which demonstrates an average MEQ30 score in the patient of at least 60%.
23. The method defined in any one of Claims 6-22, wherein the pharmaceutical composition is an injectable pharmaceutical composition.
24. The method defined in any one of Claims 6-22, wherein the pharmaceutical composition is an subcutaneous injectable pharmaceutical composition.